CHRS vs. CGEN, BDTX, CCCC, PROK, PRME, SRRK, CRGX, RGNX, TSHA, and EXAI
Should you be buying Coherus BioSciences stock or one of its competitors? The main competitors of Coherus BioSciences include Compugen (CGEN), Black Diamond Therapeutics (BDTX), C4 Therapeutics (CCCC), ProKidney (PROK), Prime Medicine (PRME), Scholar Rock (SRRK), CARGO Therapeutics (CRGX), REGENXBIO (RGNX), Taysha Gene Therapies (TSHA), and Exscientia (EXAI). These companies are all part of the "biological products, except diagnostic" industry.
Compugen (NASDAQ:CGEN) and Coherus BioSciences (NASDAQ:CHRS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, community ranking, institutional ownership and dividends.
12.2% of Compugen shares are owned by institutional investors. Comparatively, 72.8% of Coherus BioSciences shares are owned by institutional investors. 9.5% of Compugen shares are owned by insiders. Comparatively, 7.6% of Coherus BioSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Compugen has a net margin of 0.00% compared to Compugen's net margin of -19.64%. Compugen's return on equity of 0.00% beat Coherus BioSciences' return on equity.
Coherus BioSciences received 132 more outperform votes than Compugen when rated by MarketBeat users. Likewise, 65.13% of users gave Coherus BioSciences an outperform vote while only 64.35% of users gave Compugen an outperform vote.
Compugen has a beta of 2.72, indicating that its share price is 172% more volatile than the S&P 500. Comparatively, Coherus BioSciences has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500.
In the previous week, Compugen had 3 more articles in the media than Coherus BioSciences. MarketBeat recorded 6 mentions for Compugen and 3 mentions for Coherus BioSciences. Compugen's average media sentiment score of 0.73 beat Coherus BioSciences' score of 0.41 indicating that Coherus BioSciences is being referred to more favorably in the news media.
Compugen has higher earnings, but lower revenue than Coherus BioSciences. Compugen is trading at a lower price-to-earnings ratio than Coherus BioSciences, indicating that it is currently the more affordable of the two stocks.
Compugen presently has a consensus target price of $4.00, suggesting a potential upside of 84.33%. Coherus BioSciences has a consensus target price of $8.83, suggesting a potential upside of 385.35%. Given Compugen's higher possible upside, analysts clearly believe Coherus BioSciences is more favorable than Compugen.
Summary
Compugen and Coherus BioSciences tied by winning 9 of the 18 factors compared between the two stocks.
Get Coherus BioSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Coherus BioSciences Competitors List
Related Companies and Tools
